Rambus Free cash flow decreased by 23.3% to $71.57M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.9%, from $69.54M to $71.57M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 14.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $49.84M | $43.74M | $65.90M | $40.93M | $51.75M | $73.77M | $46.46M | $31.17M | $43.69M | $43.62M | $54.06M | $36.11M | $59.09M | $52.20M | $52.50M | $69.54M | $87.85M | $82.48M | $93.30M | $71.57M |
| QoQ Change | — | -12.3% | +50.7% | -37.9% | +26.4% | +42.6% | -37.0% | -32.9% | +40.2% | -0.2% | +23.9% | -33.2% | +63.6% | -11.7% | +0.6% | +32.5% | +26.3% | -6.1% | +13.1% | -23.3% |
| YoY Change | — | — | — | — | +3.8% | +68.7% | -29.5% | -23.9% | -15.6% | -40.9% | +16.4% | +15.9% | +35.2% | +19.7% | -2.9% | +92.6% | +48.7% | +58.0% | +77.7% | +2.9% |